🚀 Hope for Stargardt Disease
Ocugen has announced FDA clearance to begin a Phase 2/3 trial of OCU410ST, a groundbreaking modifier gene therapy for Stargardt disease. Early results show slowed disease progression and vision improvements, bringing real hope to the 1 million people worldwide affected by this inherited condition.

Scientists have discovered that blocking a protein called Prox1 may allow the eye to repair itself. This breakthrough could open the door to regenerative therapies for vision loss caused by diseases like retinitis pigmentosa.

💡 Awareness Through Advertising
Our ad campaigns are about more than prizes. They spark awareness for Bardet-Biedl Syndrome, connect us daily with families across rare disease and vision loss communities, and help lift up the work of other nonprofits. Every ad is a chance to build awareness, connection, and impact.

🌟 Long-Term Results Show Promise for RP Therapy
At the 2025 ASRS meeting, researchers shared 2-year results showing that MCO-010, an optogenetic therapy, provided lasting vision improvements for patients with advanced retinitis pigmentosa. Unlike traditional gene therapies, MCO-010 is gene-agnostic, meaning it could help a broad range of patients regardless of mutation.

First Patients Treated in jCell RP Trial
jCyte has launched its Phase 2 JC02-88 trial testing jCell, a potential regenerative therapy for retinitis pigmentosa. This study could bring the first treatment option to the majority of RP patients, offering hope across all genetic subtypes.